Literature DB >> 6430809

Kinetic analysis of microbe opsonification based on stimulated polymorphonuclear leukocyte oxygenation activity.

R C Allen, M M Lieberman.   

Abstract

With Pseudomonas aeruginosa as the target microbes and polymorphonuclear leukocytes (PMNL) as effector phagocytes, the microbe-specific, immunoglobulin G (IgG)-dependent opsonic capacities of preimmune and immune sera were measured as the rate of stimulated PMNL dioxygenation of luminol yielding chemiluminescence (CL). When the reactants other than opsonin are present in concentrations that are not rate limiting, the information-effector relationship linking specific opsonin concentration to effector PMNL stimulation is described by the rate equation: L' = k'[IgG]i, where L' is the peak CL velocity (photons per minute), k' is the proportionality constant, [IgG] is the concentration of specific opsonin, and the exponent i is the order of the reaction with respect to opsonin. Since the specific opsonins were polyclonal IgG of unknown absolute serum concentration, the reciprocal rate expression, L' = k'D-i, was employed for data presentation; D is the serum dilution (final volume/initial serum volume), and the sign of i is changed to negative. The relationships of integral, first-derivative, and second-derivative expressions of the CL response to opsonin concentration are illustrated with experimentally obtained data. Based on peak CL velocity or peak CL acceleration measurements taken over different time intervals of testing, the estimated order with respect to opsonin is highest, and probably most accurate, using the shortest test interval allowing reasonably good precision of measurement. As an alternative temporal approach, microbe opsonification kinetics are analyzed based on nodal time (Tn) measurements. The Tn is the time point separating the acceleration and deceleration phases of the PMNL oxygenation response to stimulation and as such satisfies the criterion of a selected condition of PMNL activation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430809      PMCID: PMC263265          DOI: 10.1128/iai.45.2.475-482.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Phagocytic activation of a luminol-dependent chemiluminescence in rabbit alveolar and peritoneal macrophages.

Authors:  R C Allen; L D Loose
Journal:  Biochem Biophys Res Commun       Date:  1976-03-08       Impact factor: 3.575

2.  Evaluation of serum opsonic capacity by quantitating the initial chemiluminescent response from phagocytizing polymorphonuclear leukocytes.

Authors:  R C Allen
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

Review 3.  Mechanism of phagocytosis-associated oxidative metabolism in polymorphonuclear leucocytes and macrophages.

Authors:  F Rossi; D Romeo; P Patriarca
Journal:  J Reticuloendothel Soc       Date:  1972-08

4.  The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles.

Authors:  P M Henson
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

5.  Role of binding through C3b and IgG in polymorphonuclear neutrophil function: studies with trypsin-generated C3b.

Authors:  S L Newman; R B Johnston
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

6.  Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.

Authors:  M M Lieberman; D C McKissock; G L Wright
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

7.  Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

8.  Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.

Authors:  M M Lieberman; G L Wright; K M Wolcott; D C McKissock-Desoto
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

9.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

10.  Quantitative granulocyte chemiluminescence in the rapid detection of impaired opsonization of Escherichia coli.

Authors:  P Stevens; L S Young
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

View more
  6 in total

1.  Evidence for involvement of peptidoglycan in the triggering of an oxidative burst by Listeria monocytogenes in phagocytes.

Authors:  K A Remer; T Reimer; M Brcic; T W Jungi
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

2.  [The effect of taurolin on endogenous immunity and pathogen elimination in human peritonitis].

Authors:  A Billing; D Fröhlich; G Ruckdeschel
Journal:  Langenbecks Arch Chir       Date:  1992

3.  Comparative study of neutrophil activation by chemiluminescence and flow cytometry.

Authors:  M M Lieberman; D M Sachanandani; C A Pinney
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

4.  [Insufficiency of intra-abdominal immunity to infection in purulent peritonitis--sequela of disordered foreign body opsonization].

Authors:  A Billing; D Fröhlich; H Kortmann; M Jochum
Journal:  Klin Wochenschr       Date:  1989-03-15

5.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

6.  Improvement of the antibody-dependent respiratory burst assay for assessing protective immune responses to malaria.

Authors:  Annick Mansourou; Charlotte Joos; Oumy Niass; Babacar Diouf; Adama Tall; Ronald Perraut; Makhtar Niang; Aissatou Toure-Balde
Journal:  Open Biol       Date:  2022-03-16       Impact factor: 6.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.